Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022

- Adverum to present new best-corrected visual acuity (BCVA) data from the OPTIC Trial of ADVM-022 (ixoberogene soroparvovec) in wet AMD REDWOOD CITY, Calif., July 08, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM ), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that new data from the Phase 1 OPTIC study of ADVM-022 (AAV.7m8-aflibercept) development program in wet age-related macular degeneration (wet AMD) will be presented next week during the American Society of Retina Specialists (ASRS) 2022 Annual Meeting in New York City. The presentation will include new best-corrected visual acuity (BCVA) results, as well as the previously reported aflibercept protein expression data through three years post-treatment with ADVM-022 (ixoberogene soroparvovec). Oral Presentation Title: ADVM-022 (ixoberogene soroparvovec) Intravitreal Gene Therapy for Neovascular AMD: Phase 1 OPTIC Trial Update Session: Wet AMD 2 Symposium Date & Time: July 15, 2022, 8:16 – 8:22 AM EDT Presenter: Dante Pieramici, M.D., partner, California Retina Consultants Adverum intends to issue a press release concurrent with the presentation and plans to post the data presented on the Publications page in the Pipeline section of the company's website. About Wet Age-Related Macular Degeneration Wet AMD, also known as neovascular AMD or nAMD, is an advanced form of AMD, affecting approximately 10% of patients living with AMD. Wet AMD is a leading cause of blindness in patients over 65 years of age, with a prevalence of approximately 20 million individuals worldwide ... Full story available on